Woodward Diversified Capital

Corent Technology develops a cloud management platform designed to analyze software applications and determine their suitability for cloud migration. Based in Aliso Viejo, California, with additional operations in Chennai, India; Amsterdam, the Netherlands; and Singapore, the company offers several key products. SurPaaS Analyzer aids in making business decisions for cloud migration architecture, while SurPaaS Shift focuses on application scalability, backup, redundancy, and PaaS services. SurPaaS Ops assists in deploying applications to the cloud and managing their lifecycle, and SurPaaS Transform enables the conversion of web applications into SaaS models. Additionally, SurPaaS Meter allows for metering software applications, setting up subscriptions, and charging customers based on usage. Corent Technology serves a global clientele including independent software vendors, enterprises, service integrators, managed service providers, and cloud providers. The company was incorporated in 1999.

Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company specializing in the development of oncolytic viral immunotherapies for treating aggressive or difficult-to-treat solid tumors. The company's proprietary platform revolves around attenuated vaccinia viruses, with its lead product candidate, GL-ONC1 (olvimulogene nanivacirepvec), currently in Phase I/II human clinical trials. GL-ONC1 encodes Green Fluorescent Protein for tumor imaging and has shown early signs of anti-tumor activity with minimal side effects in animal models and initial human trials.